超高龄非瓣膜性房颤患者使用利伐沙班抗凝治疗的单中心经验
CSTR:
作者:
作者单位:

(空军特色医学中心心血管内科,北京 100142)

作者简介:

通讯作者:

中图分类号:

基金项目:

空军特色医学中心优秀青年基金(22YXQN024)


Single-center experience of rivaroxaban for anticoagulation in super-elderly patients with nonvalvular atrial fibrillation
Author:
Affiliation:

(Department of Cardiology, Air Force Medical Center, Beijing 100142, China)

Fund Project:

This work was supported by the Fund for Distinguished Young Scholars of the Air Force Medical Center (22YXQN024).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨利伐沙班在超高龄非瓣膜性房颤患者治疗中的常用剂量及安全性。方法 选择2017年8月至2021年4月于空军特色医学中心心血管内科住院的150例超高龄非瓣膜性房颤患者为研究对象。根据非瓣膜房颤患者出血风险HAS-BLED评分高低确定初始口服利伐沙班剂量,将患者分为低剂量组(10mg/d,78例)与中剂量组(15mg/d,72例),治疗前后监测血常规、凝血功能、肝肾功能等相关指标,随访1年内的出血事件、不良反应发生率及新发缺血性卒中的发生率。采用SPSS 19.0统计软件进行数据分析。根据数据类型,分别采用t检验、单因素方差分析或χ2检验进行组间比较。结果 连续监测1年,2组患者各有5例患者因肺部感染死亡,差异无统计学意义P>0.05)。治疗前和治疗后第1、3、6、12个月2组患者血红蛋白、血小板计数、凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原、D二聚体和肝肾功能比较,差异均无统计学意义(P>0.05)。所有患者均无再发急性脑梗死或严重出血,出现轻微出血患者经调整用药剂量后症状消失。结论 超高龄老年非瓣膜性房颤患者应用利伐沙班10mg/d抗凝治疗安全有效。

    Abstract:

    Objective To investigate the usual dose and safety of rivaroxiban in super-elderly patients with non-valvular atrial fibrillation (NVAF). Methods A total of 150 super-elderly NVAF patients were enrolled as subjects, who were hospitalized in the Department of Cardiology, Air Force Medical Center from August 2017 to April 2021. The initial oral dose of rivaroxiban was determined according to the HAS-BLED score, and the patients were divided into low-dose group (10mg/d; n=78))and medium-dose group (15mg/d; n=72). Routine blood test results, coagulation, liver functions, and kidney functions were monitored before and after the treatment. The patients were followed up for 12 months for bleeding events, incidence of adverse reactions, and incidents of new ischemic strokes. SPSS statistics 19.0 was used for data analysis. Depending on data types, t test, analysis of variance (ANOVA) or χ2 test was employed for intergroup comparison. Results Five patients died of severe pneumonia in each group during one-year follow-up, the difference being not statistically significant (P>0.05). Comparison between the two groups at 1,3, 6, and 12 months found no statistically significant differences (P>0.05) in hemoblobin, platelet counts, plasma prothrombin time (PT), activated partial thromboplastin time (APTT) , fibrinogen (FIB), D-dimer (DD), liver functions, and kidney functions. Recurrence of acute cerebral infarction and severe bleeding was not recorded. Symptoms with mild bleeding disappeared after adjusting dose. Conclusion Rivaroxaban (10 mg/d) is effective and safe for the super-elderly NVAF patients.

    参考文献
    相似文献
    引证文献
引用本文

张婧,曹钰琨,李妍妍,薛恒怡,方舟,张海涛.超高龄非瓣膜性房颤患者使用利伐沙班抗凝治疗的单中心经验[J].中华老年多器官疾病杂志,2023,22(3):181-185
DOI:10.11915/j. issn.1671-5403.2023.03.037

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2022-10-12
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-03-29
  • 出版日期:
文章二维码